Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.48 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.45 |
| ▸ | RIPK1 | Q13546 | 7/20 | 0.44 |
| ▸ | DRD2 | P14416 | 3/20 | 0.43 |
| ▸ | DRD3 | P35462 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | HTR3A | P46098 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | GLA | P06280 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15964762 | 1.00 | HPGD (0.48) | HPGDCD274RIPK1DRD2DRD3 | |
| SCHEMBL15964689 | 0.86 | RIPK1 (0.43) | RIPK1 | |
| SCHEMBL15964763 | 0.86 | RIPK1 (0.43) | RIPK1 | |
| SCHEMBL18419877 | 0.86 | RIPK1 (0.43) | RIPK1 | |
| SCHEMBL15964576 | 0.86 | RIPK1 (0.48) | RIPK1 | |
| SCHEMBL29271353 | 0.84 | RIPK1 (0.44) | HPGDRIPK1ALDH1A1 | |
| SCHEMBL15956723 | 0.83 | RIPK1 (0.48) | RIPK1 | |
| SCHEMBL17321245 | 0.83 | RIPK1 (0.44) | RIPK1 | |
| SCHEMBL15956092 | 0.83 | RIPK1 (0.48) | RIPK1 | |
| SCHEMBL31437561 | 0.82 | RIPK1 (0.45) | RIPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180098998-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED (GB) | 2018-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180098998-A1 | HETEROCYCLIC AMIDES AS KINASE INHIBITORS | CNKSR1, ARAF, MAP4K2 | HPGD 3850/4885CD274 2882/4885RIPK1 387/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.